Cullinan Therapeutics, Inc. (CGEM)
19.97
-0.62
(-3.01%)
USD |
NASDAQ |
Sep 14, 10:49
Cullinan Therapeutics Enterprise Value : 996.62M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 996.62M |
| September 10, 2026 | 1.023B |
| September 09, 2026 | 1.043B |
| September 08, 2026 | 1.068B |
| September 04, 2026 | 1.093B |
| September 03, 2026 | 1.098B |
| September 02, 2026 | 1.109B |
| September 01, 2026 | 1.074B |
| August 31, 2026 | 1.092B |
| August 28, 2026 | 1.068B |
| August 27, 2026 | 1.126B |
| August 26, 2026 | 1.143B |
| August 25, 2026 | 1.149B |
| August 24, 2026 | 1.076B |
| August 21, 2026 | 1.067B |
| August 20, 2026 | 1.048B |
| August 19, 2026 | 1.121B |
| August 18, 2026 | 1.013B |
| August 17, 2026 | 996.62M |
| August 14, 2026 | 980.48M |
| August 13, 2026 | 935.30M |
| August 12, 2026 | 932.71M |
| August 11, 2026 | 934.65M |
| August 10, 2026 | 847.51M |
| August 07, 2026 | 812.00M |
| Date | Value |
|---|---|
| August 06, 2026 | 826.21M |
| August 05, 2026 | 804.26M |
| August 04, 2026 | 800.39M |
| August 03, 2026 | 716.47M |
| July 31, 2026 | 732.61M |
| July 30, 2026 | 798.45M |
| July 29, 2026 | 778.44M |
| July 28, 2026 | 795.22M |
| July 27, 2026 | 792.64M |
| July 24, 2026 | 771.34M |
| July 23, 2026 | 782.96M |
| July 22, 2026 | 806.84M |
| July 21, 2026 | 833.31M |
| July 20, 2026 | 797.16M |
| July 17, 2026 | 809.42M |
| July 16, 2026 | 726.80M |
| July 15, 2026 | 818.46M |
| July 14, 2026 | 814.59M |
| July 13, 2026 | 821.04M |
| July 10, 2026 | 837.82M |
| July 09, 2026 | 853.96M |
| July 08, 2026 | 857.19M |
| July 07, 2026 | 839.76M |
| July 06, 2026 | 817.17M |
| July 02, 2026 | 805.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Rallybio Corp. | -3.295M |
| MapLight Therapeutics, Inc. | 287.94M |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.70M |
| Total Expenses (Quarterly) | 53.70M |
| EPS Diluted (Quarterly) | -0.8666 |
| Earnings Yield | -16.99% |
| Normalized Earnings Yield | -16.99 |